Adma Biologics Share Price (NASDAQ: ADMA)

$17.25

▲

-0.13

(-0.75%)

Last updated on August 30, 2025 at 1:29 am IST

$₹

Check the interactive Adma Biologics Stock chart to analyse performance

Adma Biologics stock performance

as on August 30, 2025 at 1:29 am IST

Today's Low:$17.16
Today's High:$17.37
$17.25
0.52%
Downside
Day's Volatility :1.21%
Upside
0.69%
52 Weeks Low:$13.50
52 Weeks High:$25.67
$17.25
21.74%
Downside
52 Weeks Volatility :47.41%
Upside
32.8%

Adma Biologics Stock Returns

Period	Adma Biologics Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	-15.54%	3.6%	0.0%
6 Months	9.0%	-7.7%	0.0%
1 Year	4.13%	-12.6%	0.0%
3 Years	541.45%	9.5%	-4.7%

Adma Biologics Inc Key Stats

Check Adma Biologics key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$17.38
Open	$17.34
Today's High	$17.37
Today's Low	$17.16
Market Capitalization	$4.1B
Today's Volume	$2.5M
52 Week High	$25.67
52 Week Low	$13.5
Revenue TTM	$474.2M
EBITDA	$163.6M
Earnings Per Share (EPS)	$0.85
PE Ratio	20.31
Profit Margin	44.06%
Quarterly Earnings Growth YOY	0.08%
Return On Equity TTM	71.23%

Stock Returns calculator for Adma Biologics Stock including INR - Dollar returns

The Adma Biologics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Adma Biologics investment value today

Current value as on today

₹1,04,938

Returns

₹4,938

(+4.94%)

Returns from Adma Biologics Stock

₹347 (-0.35%)

Dollar Returns*

₹5,284 (+5.28%)

Indian investors sentiment towards Adma Biologics Stock

23.81%

Period: Jul 31, 2025 to Aug 30, 2025. Change in 30 Days versus previous period

Investment in Adma Biologics Shares from India has grown by 23.81% over the past 30 days, indicating increased transactional activity.

-14%

Period: Jul 31, 2025 to Aug 30, 2025. Change in 30 Days versus previous period

Search interest for Adma Biologics Stock from India on INDmoney has decreased by -14% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Adma Biologics Inc

Name
Holdings %
Name
Holdings %
BlackRock Inc
15.63%
Vanguard Group Inc
8.96%
Amvescap Plc.
5.39%
State Street Corp
4.80%
Geode Capital Management, LLC
2.38%
Morgan Stanley - Brokerage Accounts
2.06%

Analyst Recommendation on Adma Biologics Stock

Rating

Trend

Buy

90%Buy

10%Hold

0%Sell

Based on 10 Wall street analysts offering stock ratings for Adma Biologics(by analysts ranked 0 to 5 stars)

Adma Biologics Share Price Target

What analysts predicted

Upside of 68.46%

Target:

$29.06

Current:

$17.25

Adma Biologics share price target is $29.06, a slight Upside of 68.46% compared to current price of $17.25 as per analysts' prediction.

Adma Biologics Stock Insights

Price Movement
In the last 3 years, ADMA stock has moved up by 553.6%
Increasing Revenue
Revenue is up for the last 2 quarters, 114.80M → 121.98M (in $), with an average increase of 5.9% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, 26.90M → 34.21M (in $), with an average increase of 21.4% per quarter
ADMA vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 69.9% return, outperforming this stock by 70.2%
Price to Sales
ForADMA every $1 of sales, investors are willing to pay $8.6, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $23.5 for every $1 of sales.

Adma Biologics Inc Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$29.3M	↑ 72.79%
Net Income	$-57.0M	↓ 13.23%
Net Profit Margin	-194.37%	↑ 192.69%

	FY20	Y/Y Change
Revenue	$42.2M	↑ 43.85%
Net Income	$-87.6M	↑ 53.57%
Net Profit Margin	-207.5%	↓ 13.13%

	FY21	Y/Y Change
Revenue	$80.9M	↑ 91.72%
Net Income	$-84.5M	↓ 3.6%
Net Profit Margin	-104.34%	↑ 103.16%

	FY22	Y/Y Change
Revenue	$154.1M	↑ 90.36%
Net Income	$-85.2M	↑ 0.86%
Net Profit Margin	-55.29%	↑ 49.05%

	FY23	Y/Y Change
Revenue	$258.2M	↑ 67.59%
Net Income	$-28.2M	↓ 66.85%
Net Profit Margin	-10.94%	↑ 44.35%

	FY24	Y/Y Change
Revenue	$426.5M	↑ 65.15%
Net Income	$197.7M	↓ 800.0%
Net Profit Margin	46.35%	↑ 57.29%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$81.9M	↑ 10.79%
Net Income	$17.8M	↓ 200.92%
Net Profit Margin	21.75%	↑ 45.63%

	Q2 FY24	Q/Q Change
Revenue	$107.2M	↑ 30.92%
Net Income	$32.1M	↑ 80.06%
Net Profit Margin	29.91%	↑ 8.16%

	Q3 FY24	Q/Q Change
Revenue	$119.8M	↑ 11.8%
Net Income	$35.9M	↑ 12.0%
Net Profit Margin	29.96%	↑ 0.05%

	Q4 FY24	Q/Q Change
Revenue	$117.5M	↓ 1.91%
Net Income	$111.9M	↑ 211.61%
Net Profit Margin	95.19%	↑ 65.23%

	Q1 FY25	Q/Q Change
Revenue	$114.8M	↓ 2.34%
Net Income	$26.9M	↓ 75.96%
Net Profit Margin	23.44%	↓ 71.75%

	Q2 FY25	Q/Q Change
Revenue	$122.0M	↑ 6.26%
Net Income	$34.2M	↑ 27.19%
Net Profit Margin	28.05%	↑ 4.61%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$-10.2M	↓ 59.72%

	FY20	Y/Y Change
Profit	$-19.1M	↑ 87.8%

	FY21	Y/Y Change
Profit	$1.2M	↓ 106.15%

	FY22	Y/Y Change
Profit	$35.3M	↑ 2905.68%

	FY23	Y/Y Change
Profit	$88.9M	↑ 152.21%

	FY24	Y/Y Change
Profit	$219.6M	↑ 146.85%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$38.9M	↑ 25.94%

	Q2 FY24	Q/Q Change
Profit	$57.3M	↑ 47.27%

	Q3 FY24	Q/Q Change
Profit	$59.7M	↑ 4.1%

	Q4 FY24	Q/Q Change
Profit	$63.3M	↑ 6.16%

	Q1 FY25	Q/Q Change
Profit	$61.1M	↓ 3.53%

	Q2 FY25	Q/Q Change
Profit	$67.2M	↑ 10.03%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$-76.2M	↑ 21.56%
Investing Cash Flow	$-3.8M	↑ 81.9%
Financing Cash Flow	$80.0M	↑ 86.39%

	FY20	Y/Y Change
Operating Cash Flow	$-102.0M	↑ 33.87%
Investing Cash Flow	$-12.7M	↑ 233.82%
Financing Cash Flow	$143.9M	↑ 79.86%

	FY21	Y/Y Change
Operating Cash Flow	$-112.4M	↑ 10.16%
Investing Cash Flow	$-13.5M	↑ 6.18%
Financing Cash Flow	$121.0M	↓ 15.88%

	FY22	Y/Y Change
Operating Cash Flow	$-59.5M	↓ 47.04%
Investing Cash Flow	$-13.9M	↑ 2.96%
Financing Cash Flow	$108.9M	↓ 10.08%

	FY23	Y/Y Change
Operating Cash Flow	$8.8M	↓ 114.79%
Investing Cash Flow	$-5.0M	↓ 64.19%
Financing Cash Flow	$-39.0M	↓ 135.82%

	FY24	Y/Y Change
Operating Cash Flow	$118.7M	↑ 1248.55%
Investing Cash Flow	$-8.6M	↑ 72.15%
Financing Cash Flow	$-58.3M	↑ 49.53%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$-2.2M	↓ 112.61%
Investing Cash Flow	$-2.4M	↑ 67.85%
Financing Cash Flow	$-1.4M	↓ 96.29%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$45.6M	↓ 2157.98%
Investing Cash Flow	$-2.4M	↑ 0.13%
Financing Cash Flow	$-362.0K	↓ 74.98%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$25.0M	↓ 45.17%
Investing Cash Flow	$-1.1M	↓ 53.57%
Financing Cash Flow	$-25.5M	↑ 6935.08%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$50.2M	↑ 100.64%
Investing Cash Flow	$-2.8M	↑ 150.46%
Financing Cash Flow	$-31.0M	↑ 21.83%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$-19.7M	↓ 139.18%
Investing Cash Flow	$-4.7M	↑ 71.64%
Financing Cash Flow	$-7.1M	↓ 77.03%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$21.1M	↓ 207.44%
Investing Cash Flow	$-2.5M	↓ 46.46%
Financing Cash Flow	$48.0K	↓ 100.67%

Adma Biologics Technicals Summary

Sell

Neutral

Buy

Adma Biologics is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Adma Biologics Inc Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Adma Biologics Inc	-10.73%	9.0%	4.13%	541.45%	750.0%
Regeneron Pharmaceuticals, Inc.	6.48%	-15.2%	-50.31%	-3.3%	-2.01%
Beone Medicines Ltd	1.77%	24.81%	62.78%	79.11%	29.69%
Vertex Pharmaceuticals Incorporated	-14.45%	-19.13%	-17.84%	34.68%	41.87%
Alnylam Pharmaceuticals, Inc.	13.79%	83.28%	75.87%	111.28%	242.25%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Adma Biologics Inc	20.31	20.31	0.0	0.56	0.71	0.21	NA	1.67
Regeneron Pharmaceuticals, Inc.	14.6	14.6	1.2	39.42	0.15	0.07	0.0	287.55
Beone Medicines Ltd	NA	NA	NA	2.73	-0.05	-0.01	NA	34.32
Vertex Pharmaceuticals Incorporated	27.86	27.86	0.58	18.06	0.23	0.13	NA	67.02
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	3.92	-2.58	-0.03	NA	1.91

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Adma Biologics Inc	Buy	$4.1B	750.0%	20.31	44.06%
Regeneron Pharmaceuticals, Inc.	Buy	$61.4B	-2.01%	14.6	31.37%
Beone Medicines Ltd	NA	$36.5B	29.69%	NA	-3.89%
Vertex Pharmaceuticals Incorporated	Buy	$100.5B	41.87%	27.86	31.86%
Alnylam Pharmaceuticals, Inc.	Buy	$59.5B	242.25%	NA	-12.96%

About Adma Biologics Inc

ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Organization	Adma Biologics
Employees	685
CEO	Mr. Adam S. Grossman
Industry	Health Technology

Key Management of Adma Biologics Inc

Name	Title
Mr. Adam S. Grossman	Co-Founder, President, CEO & Director
Dr. Jerrold B. Grossman D.P.S., Ph.D.	Co-Founder & Vice Chairman of the Board
Mr. Brad Tade	CFO & Treasurer
Ms. Kaitlin Kestenberg	COO & Senior VP of Compliance
Mr. Michael Goldstein	General Counsel
Mr. John Hafl	Executive Director of Sales
Ms. Cindy Petersen	Vice President of Human Resources
Mr. Skyler Bloom	Senior Director of Business Development & Corporate Strategy

Important FAQs about investing in ADMA Stock from India :

What is Adma Biologics share price today?

Adma Biologics share price today is $17.25 as on August 30, 2025 at 1:29 am IST at the close of the market. Adma Biologics share today touched a day high of $17.37 and a low of $17.16.

What is the 52 week high and 52 week low for Adma Biologics share?

Adma Biologics share touched a 52 week high of $25.67 and a 52 week low of $13.50. Adma Biologics stock price today i.e. August 30, 2025 at 1:29 am IST is closed at $17.25, lower by 32.8% versus the 52 week high.

How to invest in Adma Biologics Stock (ADMA) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Adma Biologics on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Adma Biologics Shares that will get you 0.0870 shares as per Adma Biologics share price of $17.25 per share as on August 30, 2025 at 1:29 am IST.

What is the minimum amount required to buy Adma Biologics Stock (ADMA) from India?

Indian investors can start investing in Adma Biologics (ADMA) shares with as little as ₹88.286 or $1 (as of August 31, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹882.86 in Adma Biologics stock (as per the Rupee-Dollar exchange rate as on August 31, 2025). Based on Adma Biologics share’s latest price of $17.25 as on August 30, 2025 at 1:29 am IST, you will get 0.5797 shares of Adma Biologics. Learn more about fractional shares .

What are the returns that Adma Biologics has given to Indian investors in the last 5 years?

Adma Biologics stock has given 750.0% share price returns and 20.51% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?